Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.

Michalarea V, Fontana E, Garces AI, Williams A, Smyth EC, Picchia S, Rao S, Chau I, Cunningham D, Bali MA.

Curr Probl Cancer. 2019 Feb 21. pii: S0147-0272(18)30318-0. doi: 10.1016/j.currproblcancer.2019.01.008. [Epub ahead of print]

PMID:
30827742
2.

Genomic loss of heterozygosity and survival in the REAL3 trial.

Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, Harding TC, Nguyen M, Okines AF, Raponi M, Rao S, Watkins D, Starling N, Middleton GW, Wadsley J, Mansoor W, Crosby T, Wotherspoon A, Chau I, Cunningham D.

Oncotarget. 2018 Nov 30;9(94):36654-36665. doi: 10.18632/oncotarget.26336. eCollection 2018 Nov 30.

3.

Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer.

Chénard-Poirier M, Smyth EC.

Drugs. 2019 Jan;79(1):1-10. doi: 10.1007/s40265-018-1032-1.

PMID:
30604292
4.

Two steps forward and one step back.

Lordick F, Smyth EC.

Nat Rev Clin Oncol. 2019 Feb;16(2):69-70. doi: 10.1038/s41571-018-0154-4. No abstract available.

PMID:
30575811
5.

A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.

Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A.

Ann Oncol. 2018 Dec 1;29(12):2356-2362. doi: 10.1093/annonc/mdy407.

6.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502.

PMID:
30475956
7.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):34-43. doi: 10.1093/annonc/mdy498.

PMID:
30475943
8.

Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed.

Smyth EC, Cervantes A.

Ann Oncol. 2018 Oct 1;29(10):2027-2028. doi: 10.1093/annonc/mdy331. No abstract available.

PMID:
30137184
9.

MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way.

Smyth EC, Fitzgerald RC.

JAMA Oncol. 2018 Dec 1;4(12):1698-1699. doi: 10.1001/jamaoncol.2018.2803. No abstract available.

PMID:
30098141
10.

Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma.

Smyth EC, Petty RD.

Lancet. 2018 Jul 14;392(10142):97-98. doi: 10.1016/S0140-6736(18)31277-7. Epub 2018 Jun 4. No abstract available.

PMID:
29880232
11.

Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future.

Aggelis V, Cunningham D, Lordick F, Smyth EC.

Ann Oncol. 2018 Jun 1;29(6):1377-1385. doi: 10.1093/annonc/mdy183.

PMID:
29771279
12.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

13.

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.

Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM, Panni S, Ratti M, Lazzarelli S, Gerevini F, Colombi C, Panni A, Rovatti M, Treccani L, Martinotti M, Passalacqua R.

Oncotarget. 2017 Dec 4;8(67):111795-111806. doi: 10.18632/oncotarget.22909. eCollection 2017 Dec 19.

14.

The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients.

Polom K, Marrelli D, Smyth EC, Voglino C, Roviello G, Pascale V, Varas J, Vindigni C, Roviello F.

Surg Innov. 2018 Apr;25(2):99-104. doi: 10.1177/1553350617751461. Epub 2018 Jan 5.

PMID:
29303062
15.

Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma.

Michalarea V, Smyth EC.

J Thorac Dis. 2017 Sep;9(9):2868-2870. doi: 10.21037/jtd.2017.08.148. No abstract available.

16.

Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer-Is There Room for Improvement?

Smyth EC, Cunningham D.

JAMA Oncol. 2018 Jan 1;4(1):38-39. doi: 10.1001/jamaoncol.2017.2792. No abstract available.

17.

Emerging molecular targets and therapy for cholangiocarcinoma.

Kayhanian H, Smyth EC, Braconi C.

World J Gastrointest Oncol. 2017 Jul 15;9(7):268-280. doi: 10.4251/wjgo.v9.i7.268. Review.

18.

Oesophageal cancer.

Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D.

Nat Rev Dis Primers. 2017 Jul 27;3:17048. doi: 10.1038/nrdp.2017.48. Review.

19.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply.

Smyth EC, Allum WH, Rowley S, Langley RE, Cunningham D.

Lancet Oncol. 2017 May;18(5):e244. doi: 10.1016/S1470-2045(17)30261-9. No abstract available.

PMID:
28495289
20.

Regorafenib in gastric cancer.

Smyth EC.

Transl Gastroenterol Hepatol. 2017 Mar 15;2:16. doi: 10.21037/tgh.2017.01.07. eCollection 2017. No abstract available.

21.

Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma.

Smyth EC, Babina IS, Turner NC.

Cancer Discov. 2017 Mar;7(3):248-249. doi: 10.1158/2159-8290.CD-17-0057.

22.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D.

JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762.

23.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.

Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE.

Lancet Oncol. 2017 Mar;18(3):357-370. doi: 10.1016/S1470-2045(17)30043-8. Epub 2017 Feb 3.

24.

Immunotherapy for Gastroesophageal Cancer.

Goode EF, Smyth EC.

J Clin Med. 2016 Sep 22;5(10). pii: E84. doi: 10.3390/jcm5100084. Review.

25.

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v38-v49. No abstract available.

PMID:
27664260
26.

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma.

Davidson M, Smyth EC, Cunningham D.

Onco Targets Ther. 2016 Jul 25;9:4539-48. doi: 10.2147/OTT.S84153. eCollection 2016. Review.

27.

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N.

J Clin Oncol. 2016 Aug 10;34(23):2721-7. doi: 10.1200/JCO.2015.65.7692. Epub 2016 Jun 13.

28.

Encouraging results for PD-1 inhibition in gastric cancer.

Smyth EC, Cunningham D.

Lancet Oncol. 2016 Jun;17(6):682-683. doi: 10.1016/S1470-2045(16)30094-8. Epub 2016 May 3. No abstract available.

PMID:
27157490
29.

Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?

Fontana E, Smyth EC, Cunningham D.

Curr Treat Options Oncol. 2016 May;17(5):21. doi: 10.1007/s11864-016-0395-3. Review.

PMID:
27032643
30.

Novel targets in the treatment of advanced gastric cancer: a perspective review.

Fontana E, Smyth EC.

Ther Adv Med Oncol. 2016 Mar;8(2):113-25. doi: 10.1177/1758834015616935. Review.

31.

Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma.

Tarazona N, Smyth EC, Peckit C, Chau I, Watkins D, Rao S, Starling N, Cunningham D.

Ther Adv Med Oncol. 2016 Mar;8(2):104-12. doi: 10.1177/1758834015621669.

32.

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study.

Moorcraft SY, Fontana E, Cunningham D, Peckitt C, Waddell T, Smyth EC, Allum W, Thompson J, Rao S, Watkins D, Starling N, Chau I.

BMC Cancer. 2016 Feb 17;16:112. doi: 10.1186/s12885-016-2145-0.

33.

AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab: A Fresh Approach to an Old Puzzle.

Smyth EC, Khan K, Cunningham D.

JAMA Oncol. 2016 Feb 11. doi: 10.1001/jamaoncol.2015.6274. [Epub ahead of print] No abstract available.

PMID:
26869404
34.

Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?

Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I.

Clin Colorectal Cancer. 2016 Jun;15(2):e53-9. doi: 10.1016/j.clcc.2015.11.003. Epub 2015 Nov 27.

PMID:
26747392
35.

Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.

Fontana E, Smyth EC, Cunningham D, Rao S, Watkins D, Allum WH, Thompson J, Waddell T, Peckitt C, Chau I, Starling N.

Gastric Cancer. 2016 Oct;19(4):1114-1124. doi: 10.1007/s10120-015-0561-5. Epub 2015 Nov 5.

PMID:
26541768
36.

Personalizing the management of gastroesophageal cancer.

Smyth EC.

Per Med. 2015 Sep;12(5):447-451. doi: 10.2217/pme.15.26. Epub 2015 Sep 21. No abstract available.

PMID:
29749888
37.

Epirubicin, Cisplatin, and Capecitabine Versus Fluorouracil, Leucovorin, and Irinotecan for Esophagogastric Cancer: The Original and the Rest.

Smyth EC, Cunningham D.

J Clin Oncol. 2015 Jul 20;33(21):2409. doi: 10.1200/JCO.2014.59.7088. Epub 2015 Jun 15. No abstract available.

PMID:
26077239
38.

The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting.

Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Williams R, Cunningham D, Mudan S.

Ann Surg Oncol. 2015 Dec;22(13):4353-62. doi: 10.1245/s10434-015-4481-8. Epub 2015 Mar 13.

PMID:
25773876
39.

Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.

Zhang S, Tan IB, Sapari NS, Grabsch HI, Okines A, Smyth EC, Aoyama T, Hewitt LC, Inam I, Bottomley D, Nankivell M, Stenning SP, Cunningham D, Wotherspoon A, Tsuburaya A, Yoshikawa T, Soong R, Tan P.

J Mol Diagn. 2015 May;17(3):242-50. doi: 10.1016/j.jmoldx.2014.12.001. Epub 2015 Mar 4.

40.

Reply to R.C. Turkington et al.

Davies AR, Gossage JA, Zylstra JL, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC.

J Clin Oncol. 2015 Mar 20;33(9):1089-90. doi: 10.1200/JCO.2014.59.9506. Epub 2015 Feb 2. No abstract available.

PMID:
25646188
41.

A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.

Neofytou K, Giakoustidis A, Smyth EC, Cunningham D, Mudan S.

J Surg Oncol. 2015 May;111(6):768-70. doi: 10.1002/jso.23867. Epub 2014 Dec 29.

PMID:
25556724
42.

Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.

Smyth EC, Tarazona N, Chau I.

Immunotherapy. 2014;6(11):1177-86. doi: 10.2217/imt.14.85. Review.

PMID:
25496333
43.

Ramucirumab: successfully targeting angiogenesis in gastric cancer.

Javle M, Smyth EC, Chau I.

Clin Cancer Res. 2014 Dec 1;20(23):5875-81. doi: 10.1158/1078-0432.CCR-14-1071. Epub 2014 Oct 3. Review.

44.

Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor.

Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D, Mudan S.

Med Oncol. 2014 Oct;31(10):239. doi: 10.1007/s12032-014-0239-6. Epub 2014 Sep 14.

PMID:
25218270
45.

Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.

Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, Tesauro M, Cereda V, Guadagni F, Roselli M.

Med Oncol. 2014 Sep;31(9):166. doi: 10.1007/s12032-014-0166-6. Epub 2014 Aug 23.

PMID:
25148896
46.

Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.

Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC.

J Clin Oncol. 2014 Sep 20;32(27):2983-90.

PMID:
25071104
47.

Optimal management of esophageal adenocarcinoma: should we be CROSS?

Smyth EC, Waddell TS, Cunningham D.

J Clin Oncol. 2014 Sep 20;32(27):3080-1. doi: 10.1200/JCO.2014.55.5243. Epub 2014 Jul 28. No abstract available.

PMID:
25071100
48.

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.

Smyth EC, Sclafani F, Cunningham D.

Onco Targets Ther. 2014 Jun 12;7:1001-14. doi: 10.2147/OTT.S44941. eCollection 2014. Review.

49.

Operable gastro-oesophageal junctional adenocarcinoma: Where to next?

Smyth EC, Cunningham D.

World J Gastrointest Oncol. 2014 Jun 15;6(6):145-55. doi: 10.4251/wjgo.v6.i6.145. Review.

50.

Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?

Moorcraft SY, Smyth EC, Cunningham D.

Gastric Cancer. 2015 Jan;18(1):1-10. doi: 10.1007/s10120-014-0356-0. Epub 2014 Mar 18. Review.

PMID:
24638977

Supplemental Content

Loading ...
Support Center